Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS (Centers for Medicare and Medicaid Services) amends imaging agent fee schedule

This article was originally published in Clinica

Executive Summary

The Centers for Medicare & Medicaid Services (CMS) has lifted all restrictions on Medicare's payments for higher-cost imaging agents that reduce some of the potential complications associated with using a contrast agent. Low osmolar contrast materials are non-ionic agents that pose less risk of flushing, anxiety, nausea and vomiting. Although more expensive than other contrast materials, they have become standard practice among radiologists, the agency explained in announcing its rule change.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT059226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel